"Bulletin","Class_of_antibiotics","Antibiotic","Isolated","Resistance","95_IC_low","95_IC_upper"
"https://github.com/fbranda/amr/blob/main/bulletins/Italy/AR-ISS/AMR_AR_ISS_2019.pdf","Penicilline","Piperacillina-Tazobactam",3768,"24.1","22.7","25.5"
"https://github.com/fbranda/amr/blob/main/bulletins/Italy/AR-ISS/AMR_AR_ISS_2019.pdf","Cefalosporine III generazione","Ceftazidime",3798,"19.1","17.8","20.3"
"https://github.com/fbranda/amr/blob/main/bulletins/Italy/AR-ISS/AMR_AR_ISS_2019.pdf","Cefalosporine III generazione","Cefepime",2535,"18.2","16.7","19.7"
"https://github.com/fbranda/amr/blob/main/bulletins/Italy/AR-ISS/AMR_AR_ISS_2019.pdf","Cefalosporine III generazione","Ceftolozano-Tazobactam",261,"11.5","7.9","16.0"
"https://github.com/fbranda/amr/blob/main/bulletins/Italy/AR-ISS/AMR_AR_ISS_2019.pdf","Carbapenemi","Imipenem",1687,"18.6","16.8","20.6"
"https://github.com/fbranda/amr/blob/main/bulletins/Italy/AR-ISS/AMR_AR_ISS_2019.pdf","Carbapenemi","Meropenem",3785,"10.6","9.6","11.6"
"https://github.com/fbranda/amr/blob/main/bulletins/Italy/AR-ISS/AMR_AR_ISS_2019.pdf","Aminoglicosidi","Amikacina",3835,"4.8","4.1","5.5"
"https://github.com/fbranda/amr/blob/main/bulletins/Italy/AR-ISS/AMR_AR_ISS_2019.pdf","Aminoglicosidi","Gentamicina",3859,"11.4","10.4","12.4"
